Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Burning Rock Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.04.
Burning Rock Biotech's long-term debt to total assets ratio
increased
from Mar. 2025 (0.02) to Mar. 2026 (0.04).
It may suggest that Burning Rock Biotech is progressively becoming more dependent on debt to grow their business.
Burning Rock Biotech (FRA:6BU0) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Burning Rock Biotech LT-Debt-to-Total-Asset Related Terms
Burning Rock Biotech LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a LT-Debt-to-Total-Asset of 0.04 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's LT-Debt-to-Total-Asset too high?
Burning Rock Biotech's current LT-Debt-to-Total-Asset is 0.04. Overall, Burning Rock Biotech has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's LT-Debt-to-Total-Asset compare to XGN and IDXG?
Burning Rock Biotech's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.13, compared to a current price of €8.75 — trading 42.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Burning Rock Biotech's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €8.75 is trading 42.7% above its estimated GF Value™ of €6.13.
GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.
Key valuation signals for FRA:6BU0:
LT-Debt-to-Total-Asset: 0.04
GF Value™: €6.13 vs. price of €8.75 (42.7% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
64GF Score
Get the complete analysis for FRA:6BU0
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
